A Phase 1 Clinical Study of Autologous HBV-specific TCR-T Cell Therapy (SCG101) in Patients With HBV-related HCC
Latest Information Update: 26 May 2025
At a glance
- Drugs SCG 101 (Primary) ; Checkpoint kinase inhibitors; Cyclophosphamide; Fludarabine
- Indications Liver cancer
- Focus Adverse reactions; First in man; Proof of concept
Most Recent Events
- 08 May 2025 According to a SCG Cell Therapy media release, data from this study were presented at the European Association for the Study of the Liver (EASL) Congress 2025.
- 08 May 2025 Results presented in a SCG Cell Therapy media release.
- 25 Nov 2024 According to a SCG Cell Therapy media release, late-breaking data from its Phase 1 trial of SCG101 was presented at the 2024 AASLD Liver Meeting in San Diego, United States.